论文部分内容阅读
肝脏疾病目前已成为我国高发性疾病之一,胃肠道出血是肝脏疾病常见的并发症之一,现临床常用质子泵抑制剂类药物进行治疗。沃诺拉赞作为一种新型的质子泵抑制剂,可能可以替代目前常用的兰索拉唑作为临床有效抑制胃酸的药物。本实验主要探索并研究了沃诺拉赞在四氯化碳诱导的急性肝损伤大鼠血浆中的经时过程及其主要代谢物的生成情况。结果表明,在急性肝损伤大鼠体内,沃诺拉赞暴露量显著高于正常大鼠,代谢物生成速率降低,这可能是由于肝损伤影响了酶活性及转运体活性导致的。本研究为今后临床对肝脏疾病患者的用药调整提供了一定的理论依据。
Liver disease has become one of the most serious diseases in our country. Gastrointestinal hemorrhage is one of the common complications of liver diseases. Now it is commonly used in the treatment of proton pump inhibitors. As a new type of proton pump inhibitor, Volanizan may be an alternative to lansoprazole currently used as a clinically effective gastric acid suppressive drug. This experiment mainly explored and studied the time course and the production of major metabolites of vinorelazine in the plasma of CCl4-induced acute liver injury rats. The results showed that the Wollazane exposure in rats with acute liver injury was significantly higher than that in normal rats and the rate of metabolite production was decreased. This may be due to the liver injury affecting the enzyme activity and the transporter activity. This study provides a theoretical basis for the future clinical use of drugs in patients with liver diseases.